Comparative Pharmacology
Head-to-head clinical analysis: CLEMASTINE FUMARATE versus HISTAFED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEMASTINE FUMARATE versus HISTAFED.
CLEMASTINE FUMARATE vs HISTAFED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clemastine fumarate is a competitive antagonist of histamine at H1-receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, bronchoconstriction, and pruritus. It also exhibits anticholinergic and sedative effects.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
1.34 mg orally twice daily; max 8.04 mg/day
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
None Documented
None Documented
Terminal elimination half-life: 21 ± 6 hours. Provides sustained antihistamine effect, allowing twice-daily dosing.
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Primarily renal (45-55% as unchanged drug and metabolites) and fecal (30-40%), with biliary excretion contributing minorly.
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination